Streetbeat News

Regulatory

DHCA

Brand Engagement Network (BEN) and DHC Acquisition Corp. (NASDAQ:DHCA) announced the SEC's approval of their Registration Statement for a proposed business combination. The extraordinary general meeting for DHC shareholders to vote on this merger is scheduled for March 5, 2024. The merger, expected to close shortly after the meeting, will result in the combined entity listing on Nasdaq under the ticker 'BNAI'. BEN's leadership believes this move will advance their mission of creating AI-driven customer engagement solutions.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:07 pm

PBLA

Panbela Therapeutics announced it has regained compliance with Nasdaq's listing requirements, avoiding the risk of delisting.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:05 pm

VSTE

Vast Renewables Limited received a Nasdaq non-compliance notice due to not meeting the Market Value of Publicly Held Shares Standard. The company has until August 7, 2024, to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:03 pm

CRDL

Cardiol Therapeutics announced that the FDA has granted Orphan Drug Designation to its lead drug candidate for the treatment of pericarditis. This designation is significant as it provides various benefits including tax credits, eligibility for market exclusivity, and assistance in the drug development process.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:30 pm

PRQR

ProQR announced that its Japanese patent for Axiomer, related to ADAR-mediated RNA editing, has been upheld following an opposition against its intellectual property estate. This development reinforces ProQR's IP position in the RNA editing space, a key area for therapeutic advancements.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:20 pm

META

Meta's decision to remove political content from Instagram and Threads recommendations has spotlighted Bluesky, a decentralized social media platform offering customizable feeds and user autonomy. Bluesky, backed by Jack Dorsey, has seen significant user growth, nearly doubling its base to 5 million. This contrasts with Meta's centralized control and recent moves to enhance election safeguards for 2024. Bluesky's integration with ActivityPub and its open approach to user content preferences position it as a strong competitor to Meta.

Portfolio Pulse from Benzinga Neuro

February 15, 2024 | 12:13 pm

IONS

The FDA has awarded Orphan Drug Designation to Ionis Pharmaceuticals for Olezarsen, a treatment for Familial Chylomicronemia Syndrome.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:04 pm

ALVO

JNJ

Alvotech has reached a settlement with Johnson & Johnson regarding the market entry of AVT04, a biosimilar to Stelara, in certain markets. AVT04 is expected to enter the Canadian market in Q1 2024, Japan in May 2024, and the first European markets in July 2024. Regulatory approval for AVT04 has been granted in these regions, with applications pending in additional markets, including the U.S.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 11:38 am

CLF

Cleveland-Cliffs announced it will indefinitely idle its tinplate production plant in Weirton, West Virginia, in April 2024 due to an unfavorable ruling from the International Trade Commission (ITC).

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 11:06 am

LCID

Lucid USA is recalling 189 of its 2022-2024 Air vehicles due to a software issue in versions 2.1.2 through 2.1.26 that may cause a fault when the adaptive cruise control is activated, leading to a loss of drive power.

Portfolio Pulse from Charles Gross

February 15, 2024 | 10:36 am